Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the rate of radiological disease progression with the new 2nd generation
positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with
metastatic castration (mCRPC) and non-metastatic (nmCRPC) castration resistant prostate
cancer who have evidence of biochemical (PSA) disease progression without evidence of
radiological disease progression on conventional standard radiologic testing (99mTc-methylene
diphosphonate bone scan and CT).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins